GENE ONLINE|News &
Opinion
Blog

2021-11-10| China

Zai Lab Buys Rights to Three Assets, Including Its First Neuroscience Drug

by Joy Lin
Share To
Until recently, Zai Lab had been content with cultivating their collection of oncology assets, along with a few drugs targeting infectious and autoimmune diseases. That's why their latest deal, struck Tuesday with Blueprint Medicines for rights to two cancer drugs, seemed to be business as usual.

However, on the same day, the Chinese company marked a sudden shift in strategy by in-licensing their first neuroscience asset from another company, Karuna Therapeutics. The licensing deal with Karuna gives Zai Lab rights to the former's KarXT for development and commercialization in mainland China, Hong Kong, Macau, and Taiwan.

In its second collaboration, Zai Lab bought rights to develop and sell two Blueprint Medicines' lung cancer drugs, BLU-945 and BLU701, in China, Hong Kong, Macau, and Taiwan.

GO Prime with only $1.49 now

LATEST
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!